九典制药：洛索洛芬钠凝胶贴膏属于公司成熟产品

Core Viewpoint - The company indicates that the recent centralized procurement requires national medical institutions to prioritize the use of selected products, which will impact the company's revenue and profit performance in the short term due to adjustments in profit margins for its mature product, Loxoprofen Sodium Gel Patch [2] Group 1 - The centralized procurement mandates that medical institutions ensure the completion of agreed procurement volumes for selected products [2] - Loxoprofen Sodium Gel Patch is identified as a mature product of the company [2] - The current procurement pricing mechanism is expected to lead to a phase adjustment in profit margins [2]